Tissue damage leads to rupture of vessels which triggers hemostatic mechanism. Hemostasis is a physiological mechanism of the body, wherein vessels contract, platelet plugs are formed, and coagulation starts, resulting in a stable fibrin network. Fibrinolysis is activated during this mechanism. Fibrinolysis is a physiological process in which blood clots are dissolved and tissue damage is remolded. Antifibrinolytic drugs are used to induce clot formation and to prevent blood loss in traumatic injuries. These drugs inhibit the activation of plasminogen to plasmin, thus preventing fibrinolysis and maintaining clot stability. Antifibrinolytic drugs are commonly known as fibrinolytic inhibitors. Reduction of fibrinolytic activity with antifibrinolytic drugs is important in trauma and surgery to control blood loss. People suffering from bleeding disorders such as hemophilia A and B, Von Willebrand disease, and platelet dysfunctions are often treated with fibrinolytic inhibitors or antifibrinolytic drugs. Currently, epsilon-aminocaproic acid (EACA) and tranexamic acid (TA or AMCA) are the synthetic antifibrinolytic drugs available in the market. EACA is a synthetic derivative of lysine and has a strong inhibiting effect on plasminogen. TA is found to be 10 times more effective than epsilon-aminocaproic acid.
The global antifibrinolytic drugs market is anticipated to expand during the forecast period due to rise in severe road accidents, complicated medical surgeries and procedures, prevalence of angioedema, and rise in the high-risk geriatric population globally. Trauma is the second largest cause of death in people aged between five and 45 years. Each year, about three million people die due to trauma. Injuries to the central nervous system and multi-organ failure cause severe bleeding problems. In such cases, antifibrinolytic drugs play a key role in preventing lysis of clot and loss of blood. Antifibrinolytic drugs are given to patients, undergoing cardiovascular surgeries, to prevent excessive bleeding. High prevalence of bleeding disorders and rise in major surgical procedures drive the global antifibrinolytic drugs market.
The global antifibrinolytic drugs market can be segmented based on drug type, application, end-user, and region. In terms of drug type, the global market can be divided into Trasylol, Aminocaproic acid, RiaSTAP, Aprotinin, Tranexamic acid injection, Tranexamic acid oral, Lysteda, and Fibrinogen, human.
Based on application, the global antifibrinolytic drugs market can be categorized into gynecology, gastrointestinal bleeding, hereditary angioedema, hemorrhage, bleeding in nose and mouth, fibrinolytic response testing, and surgeries. The gynecology segment can be further divided into medical conditions such as menorrhagia, pregnancy, parturition, and gynecological surgeries. The surgeries segment includes dental surgeries, cardiovascular surgeries, and neurosurgeries. In terms of end-user, the global antifibrinolytic drugs market can be segmented into hospitals, ambulatory surgical centers, clinics, and health care specialty processes.
In terms of region, the global antifibrinolytic drugs market can be segmented into Europe, Latin America, Asia Pacific, North America, and Middle East & Africa. North America dominates the market in terms of revenue and is anticipated to continue its dominance during the forecast period from 2017 to 2025. Rise in awareness about antifibrinolytic drugs is likely to augment the market in North America. Growth of the market in North America can also be attributed to substantial investments in R&D and health care expenditure by the government and private players. Europe holds the second largest share of the global antifibrinolytic drugs market owing to mandatory medical insurance in countries such as Germany and France, high disposable income, and high research & development in the health care sector. The market in Asia Pacific and Middle East & Africa is attributed to expand at a significant pace during the forecast period.
Key players operating in the global antifibrinolytic drugs market are Acic Fine Chems, Xanodyne Pharmaceuticals, and Aurobindo Pharma Ltd.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.